Molecure

📣 #OATD01 news! Another significant milestone achieved: dosing of the first patient in the phase II clinical trial OATD-01 (KITE) for the treatment of pulmonary sarcoidosis at the clinical site in the UK 👩⚕️ The Phase II study will be conducted in the UK, the US, the European Union and Norway and will involve approximately 100 patients. Patients will take a daily oral dose of 25 mg OATD-01 or placebo for 12 weeks 💊 ➡️ Find out more here: https://lnkd.in/d5jNHc6t

Today we celebrate World Oncology Day, a day dedicated to supporting cancer patients, honoring doctors and researchers, and emphasizing the critical role of innovation in the fight against cancer 🎗 At #Molecure, we are committed to developing new therapies that can change the future of cancer treatment. Our second proprietary candidate, #OATD02, is currently in Phase 1 clinical trial for the potential treatment of a broad range of tumors 🔬 Through cutting-edge science, the dedication of our teams and partnerships with leading oncology experts, we are facing tough challenges to provide patients with a better tomorrow 💪🌍 #WorldOncologyDay

#Molecure is pleased to invite you to an investor meeting dedicated to discussing the Company's operational and financial situation for 1H 2024 🌟 During the meeting, we will present: 🔬 Progress in ongoing research programs 📈 Development plans for the coming quarters 🗓️ Join us TODAY at 2:00 pm (CET) PL: https://lnkd.in/dKuPhChm ENG: https://lnkd.in/dVg6f_b2

Our HR manager, Karolina Kosińska, participated in the conference Strategic Benefits&Wellbeing of Employees in the Łódzka Specjalna Strefa Ekonomiczna / Lodz Special Economic Zone last week 💼 She attended various sessions, gaining valuable insights and staying informed on the latest trends in employee well-being and benefits ✨

The H1 2024 report is now available on our website 📈 Here are some of the highlights: 🔬 Molecure focused on the development of two key molecules: #OATD01 and #OATD02, as well as expanding research activities based on, among other things, advanced artificial intelligence technologies 💊 Molecure received approval to initiate a Phase II clinical trial #KITE for #OATD01 for the treatment of pulmonary sarcoidosis in the EU and Norway. Prior to that, Molecure received approval from the US FDA and the UK MHRA 👩⚕️ Progress in the Phase I clinical trial of #OATD02, for the treatment of cancer, recruitment continues and addition of 3 more patients is underway 🤝 Strategic research collaboration with Avicenna Biosciences to optimize small-molecule drug discovery and development processes in the USP7 program 🧬 Confirmation of the ability of a second molecule, developed within the mRNA platform, to effectively bind to an established mRNA fragment and block the translation process of a pathogenic protein Click here to view the full report (section "Raporty giełdowe") ➡️ https://lnkd.in/djcwrXGn

Ahoj! 🇨🇿 Over the past 3 days, our #Molecure team, made up of Mateusz Urban (Process Chemist - Scientist II), Damian Kuśmirek (Process Chemist - Scientist II) and Piotr Pomarański (Process Chemist - Senior Scientist), attended the 52ND Organic Process Research & Development Conference #OPRDEU2024 in Prague. It was a fantastic opportunity to exchange knowledge and connect with other experts in the field! 🔬🌍

Monitoring and auditing are essential processes in clinical trials to ensure the safety of participants and the integrity of the data collected. But what exactly do these terms mean, and why are they so crucial? 🤔 Find out 👉 By maintaining rigorous monitoring and auditing practices, clinical trials can achieve the highest standards of quality and transparency, fostering trust among patients, researchers and regulatory bodies 🔬✨

On Friday, our Head of Non-clinical Safety, Anna Cabaj, and Non-clinical Safety Project Manager, Paulina Dera, attended the EUFEMED 2024 Workshop: “Making the Investigator Brochure truly fit for purpose in early medicines development” in Warsaw 🏥 The aim of the workshop was to contribute to efforts to create a more meaningful Investigator Brochure (IB) through a process for translational results’ interpretation, investigator-centered presentation, and decision-making 📝🔍 We are excited to implement these insights into our ongoing projects! 💡

Ethics are at the core of every clinical trial. Ensuring the safety, dignity and rights of participants is essential throughout the research process 👥 But what are the key ethical principles that guide clinical trials? 🤔 Find out 👉 By adhering to these ethical principles, clinical trials not only contribute to medical advancements but also respect the rights and dignity of all participants, building trust in the research process and ensuring that the outcomes benefit society as a whole 🌍🤝

Hallo! 👋 We had an incredibly insightful time at the European Respiratory Society (ERS) Congress 2024 in Vienna, Austria 🇦🇹 Our team, including our designated CMO, Piotr Iwanowski, and Medical Director, Marta Dudek MD, PhD, presented at the poster session on Sarcoidosis: Immunological Features and Biomarkers 🧬 It was a great opportunity to learn more about the latest advancements in #sarcoidosis research and to connect with so many brilliant minds in the field 🤝